Your browser is no longer supported. Please, upgrade your browser.
Settings
NTLA Intellia Therapeutics, Inc. daily Stock Chart
NTLA [NASD]
Intellia Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.96 Insider Own0.10% Shs Outstand45.71M Perf Week-3.07%
Market Cap650.00M Forward P/E- EPS next Y-2.75 Insider Trans19.63% Shs Float35.49M Perf Month-1.39%
Income-85.90M PEG- EPS next Q-0.61 Inst Own73.90% Short Float22.86% Perf Quarter-12.60%
Sales33.40M P/S19.46 EPS this Y-5.60% Inst Trans4.58% Short Ratio16.81 Perf Half Y3.64%
Book/sh5.84 P/B2.43 EPS next Y-15.00% ROA-25.40% Target Price30.81 Perf Year-51.81%
Cash/sh6.49 P/C2.19 EPS next 5Y30.00% ROE-31.70% 52W Range11.03 - 32.95 Perf YTD4.18%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-56.84% Beta-
Dividend %- Quick Ratio7.70 Sales past 5Y- Gross Margin- 52W Low28.91% ATR0.68
Employees211 Current Ratio7.70 Sales Q/Q38.70% Oper. Margin- RSI (14)44.20 Volatility4.22% 4.39%
OptionableYes Debt/Eq0.02 EPS Q/Q4.50% Profit Margin- Rel Volume0.97 Prev Close14.73
ShortableYes LT Debt/Eq0.00 EarningsAug 01 BMO Payout- Avg Volume482.60K Price14.22
Recom1.90 SMA20-1.95% SMA50-7.87% SMA200-19.24% Volume467,300 Change-3.46%
Jun-10-19Initiated ROTH Capital Neutral $16
May-03-19Upgrade Wedbush Neutral → Outperform $20 → $21
Apr-12-19Initiated Evercore ISI Outperform
Nov-02-18Downgrade Wedbush Outperform → Neutral $36 → $20
Oct-29-18Initiated Credit Suisse Neutral $24
Sep-21-18Initiated Raymond James Mkt Perform
May-15-18Upgrade Chardan Capital Markets Neutral → Buy $20 → $57.50
Mar-08-18Initiated JMP Securities Mkt Outperform $76
Nov-01-17Reiterated Jefferies Buy $36 → $42
Jun-22-17Resumed Jefferies Buy $36
Mar-28-17Initiated Chardan Capital Markets Buy $19
Aug-05-16Upgrade Jefferies Hold → Buy
May-31-16Initiated Wedbush Outperform $38
May-31-16Initiated Leerink Partners Mkt Perform
May-31-16Initiated Jefferies Hold $33
May-31-16Initiated Credit Suisse Outperform $39
Jun-14-19 09:00AM  Glaxo Inks Genome Research Deal With University of California Zacks
Jun-10-19 07:47AM  How Many Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
May-30-19 04:30PM  Intellia Therapeutics to Participate at June Healthcare Investor Conferences GlobeNewswire
May-28-19 07:50AM  Intellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer GlobeNewswire
May-09-19 07:20PM  Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy? Insider Monkey
May-07-19 04:01PM  Edited Transcript of NTLA earnings conference call or presentation 2-May-19 12:00pm GMT Thomson Reuters StreetEvents -7.66%
May-06-19 06:05PM  3 Biotech Sector ETFs Bucked the Risk-Off Trend ETF Trends +10.49%
May-02-19 01:16PM  Intellia Therapeutics, Inc. (NTLA) Q1 2019 Earnings Call Transcript Motley Fool
09:15AM  Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:30AM  Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update GlobeNewswire
Apr-29-19 07:30AM  Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy GlobeNewswire
Apr-25-19 07:30AM  Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 Earnings and Company Update GlobeNewswire
Apr-17-19 01:10PM  One-Size-Fits-All CRISPR Lock Could Catapult the Sector Forward GuruFocus.com -6.79%
07:14AM  Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag Zacks
Apr-15-19 04:30PM  Intellia Therapeutics Announces Three Oral Presentations on In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy GlobeNewswire
Apr-09-19 03:33PM  These Cannabis and China ETFs are Leading the 2019 Rally Investopedia -5.06%
Apr-03-19 04:11PM  CRISPR Biotech Inks Deal To Use Stem Cells In Gene-Editing Medicine Investor's Business Daily
Mar-12-19 07:34AM  Some Intellia Therapeutics (NASDAQ:NTLA) Shareholders Have Copped A Big 50% Share Price Drop Simply Wall St.
Mar-07-19 02:47PM  5 Top Gene-Editing Stocks for 2019 Motley Fool
Mar-01-19 04:54PM  Intellia CEO not involved in Starboard's Bristol-Myers board challenge Reuters +11.10%
03:20PM  A Specialty Biotech ETF Strengthens on Optimism Over CRISPR Advancements ETF Trends
01:57PM  Intellia CEO not involved in Starboard's Bristol-Myers board challenge Reuters
Feb-28-19 07:44PM  Intellia CEO not involved in Starboard's Bristol-Myers board challenge Reuters
Feb-27-19 06:30AM  Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results GlobeNewswire +6.34%
Feb-26-19 10:54AM  CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study Zacks
Feb-24-19 10:16AM  Better Buy: Editas Medicine vs. Intellia Therapeutics Motley Fool
Feb-06-19 07:50AM  Research Report Identifies Norfolk Southern, DENTSPLY SIRONA, Healthcare Realty Trust, PTC, Intellia Therapeutics, and El Paso Electric with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Feb-01-19 02:11PM  German firm that serves gene therapy biotechs opens Cambridge HQ American City Business Journals
01:53PM  3 Biotech Stocks That Are Set for a Breakthrough InvestorPlace
Jan-24-19 07:00AM  Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors GlobeNewswire
Jan-22-19 04:28PM  Editas CEO Resigns Sending All 3 CRISPR Stocks Into Free Fall Investor's Business Daily -6.84%
Jan-11-19 09:36AM  Here's Why Intellia Therapeutics Stock Lost 23.8% in December Motley Fool
Jan-10-19 03:36PM  The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29% Motley Fool
Jan-07-19 10:03AM  Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag Zacks
Jan-04-19 04:24PM  These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy Investor's Business Daily +6.93%
Dec-17-18 07:25AM  New Research: Key Drivers of Growth for Ashland Global, Intellia Therapeutics, Thor Industries, Zogenix, BWX Technologies, and Heidrick & Struggles International Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Dec-10-18 04:31PM  Why CRSP Stock Has Added Layers of Risk InvestorPlace
Dec-06-18 07:30AM  Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population GlobeNewswire
Nov-30-18 04:14PM  This Biotech Stock Could Launch Its First CRISPR Drug In 2022 Investor's Business Daily
10:31AM  Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018 Motley Fool
09:15AM  The Market is All Packed for Buenos Aires Zacks
Nov-28-18 01:05PM  Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns' Benzinga +6.95%
Nov-26-18 04:22PM  With genetically edited babies, a scientist transgresses a moral boundary MarketWatch
02:46PM  Mass. biotech leaders voice alarm over report of first gene-edited babies American City Business Journals
Nov-08-18 04:30PM  Intellia Therapeutics to Present at November Healthcare Investor Conferences GlobeNewswire
Nov-07-18 07:46PM  Cambridge's Editas asks FDA to start gene editing trial American City Business Journals +5.09%
01:31PM  Edited Transcript of NTLA earnings conference call or presentation 31-Oct-18 12:00pm GMT Thomson Reuters StreetEvents
07:35AM  Consolidated Research: 2018 Summary Expectations for STORE Capital, Ares Commercial Real Estate, Intellia Therapeutics, City Office REIT, RealPage, and Data I/O Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-05-18 02:13PM  Here's Why CRISPR Stocks Fell as Much as 40.7% in October Motley Fool
Nov-03-18 08:20AM  Better Buy: Editas Medicine, Inc. vs. Intellia Therapeutics, Inc. Motley Fool
Oct-31-18 11:51AM  Cambridge's Intellia delays gene editing trial American City Business Journals -8.32%
08:55AM  Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:30AM  Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments GlobeNewswire
Oct-30-18 04:30PM  Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2018 Earnings and Corporate Developments GlobeNewswire
Oct-29-18 04:30PM  Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer GlobeNewswire -6.70%
Oct-21-18 06:33AM  Better Buy: CRISPR Therapeutics AG vs. Intellia Therapeutics Inc. Motley Fool
Oct-18-18 08:30AM  Intellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society of Gene and Cell Therapy GlobeNewswire -5.27%
Oct-10-18 08:10AM  Analysis: Positioning to Benefit within Big 5 Sporting Goods, Intellia Therapeutics, IDEX, Dolby Laboratories, Quotient Technology, and Modine Manufacturing Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire -5.27%
Sep-24-18 08:30AM  Intellia Therapeutics to Present at October Healthcare Investor Conferences GlobeNewswire
Sep-10-18 04:30PM  CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology GlobeNewswire
01:52PM  U.S. appeals court upholds MIT, Harvard patents on CRISPR gene editing Reuters
Sep-04-18 11:29AM  Here's Why CRISPR Stocks Rose as Much as 18.7% in August Motley Fool
Aug-27-18 01:12PM  Gene Editing is a Major Technology to Watch InvestorPlace
Aug-23-18 04:01PM  Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratorys Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution GlobeNewswire
Aug-06-18 07:25AM  Detailed Research: Economic Perspectives on IQVIA, Intellia Therapeutics, Deluxe, Superior Industries International, The Navigators Group, and CAI International What Drives Growth in Today's Competitive Landscape GlobeNewswire
Aug-01-18 08:45AM  Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:30AM  Intellia Therapeutics Announces Second Quarter 2018 Financial Results GlobeNewswire
Jul-28-18 09:03AM  Intellia Therapeutics, Inc. Stock History: The Story of a CRISPR Gene Editing Pioneer Motley Fool
Jul-24-18 04:06PM  Here's Why CRISPR Stocks Are Down as Much as 11.4% Today Motley Fool -6.44%
Jul-17-18 03:01PM  Yet Another CRISPR Worry: What Should Investors Do? Motley Fool +6.81%
08:00AM  Today's Research Reports on Stocks to Watch: Dr. Reddy's Laboratories and Intellia Therapeutics ACCESSWIRE
Jul-16-18 07:31PM  [$$] New Research Prompts Selloff in Companies Using Crispr Technology The Wall Street Journal -9.94%
12:21PM  Gene-editing stocks tumble on concerns about DNA damage MarketWatch
07:10AM  Complimentary Technical Snapshots on Intercept Pharma and Three More Biotech Stocks ACCESSWIRE
Jun-22-18 03:12PM  Editas Medicine Stock History: The Story Behind the CRISPR Gene-Editing Pioneer Motley Fool
09:36AM  Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia Zacks
Jun-19-18 09:05AM  CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing GlobeNewswire
Jun-15-18 11:09AM  The Case for Adding Low-Fee Asset Classes to a Diversified Portfolio InvestorPlace +5.22%
Jun-13-18 06:02AM  CRISPR Could Cause Cancer? Here Are 3 Reasons Investors Shouldn't Panic Motley Fool
Jun-12-18 07:01AM  CRISPR-related stocks sink after report that gene-editing technology might cause cancer MarketWatch
Jun-11-18 04:20PM  Biotech Stocks Crispr, Editas, Intellia Fall On Gene-Editing Study Investor's Business Daily -9.81%
Jun-08-18 04:05PM  Here's Why the Top CRISPR Stocks Rose as Much as 47.1% in May Motley Fool
03:31AM  FDA Creates Potential Buying Opportunity for CRSP Investopedia
Jun-01-18 08:41AM  Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex Zacks -6.09%
May-31-18 08:31AM  4 Reasons Not to Worry About Crispr Therapeutics AG's Latest Setback Motley Fool
07:55AM  Is Crispr Therapeutics Stock a Bad News Buy? Motley Fool
May-30-18 03:37PM  What Makes This CRISPR Stock Better Than the Rest? Motley Fool +5.45%
May-17-18 07:30AM  Intellia Therapeutics Announces WT1 as Its First Cell Therapy Target, Following Presentation of Early Data at the American Society of Gene and Cell Therapy 21st Annual Meeting GlobeNewswire
May-16-18 07:00AM  CRISPR Stocks Deserve a Second Look. Here's Why. Investopedia
May-14-18 07:30AM  New Scientific Advisors Focused on Cell Therapy in Immuno-Oncology and Autoimmunity Join Intellia Therapeutics GlobeNewswire
May-01-18 04:56PM  Top Gene-Editing Stocks for Long-Term Investors Motley Fool
07:30AM  Intellia Therapeutics Announces First Quarter 2018 Financial Results GlobeNewswire
Apr-25-18 07:45AM  Consolidated Research: 2018 Summary Expectations for Caseys General Stores, EQT Midstream Partners, LP, Intellia Therapeutics, Blue Buffalo Pet Products, Life Storage, and Thor Industries Fundamental Analysis, Key Performance Indications GlobeNewswire
Apr-23-18 09:29AM  UPDATE -- Intellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell Therapy 21st Annual Meeting GlobeNewswire -6.26%
08:30AM  Intellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell Therapy 21st Annual Meeting GlobeNewswire
Apr-20-18 05:12PM  Big Week in Tech for Amazon, Alphabet and Microsoft Yahoo Finance Video
Apr-13-18 07:34AM  Why Intellia Therapeutics, Inc. Stock Lost 19.2% in March Motley Fool
Apr-03-18 09:32AM  Oops! CRISPR Concerns Turn Out to be a Big Nothingburger Motley Fool
Mar-16-18 06:13AM  3 Reasons CRISPR Stocks Could Keep Soaring Motley Fool -6.25%
Mar-14-18 02:22PM  Intellia Therapeutics Incs (NASDAQ:NTLA) Earnings Dropped -105.74%, How Did It Fare Against The Industry? Simply Wall St. -13.28%
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Ospedale San Raffaele; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHIERMEIER ANDREWEVP, Dev and Corp StrategyMar 06Buy15.727,500117,8757,500Mar 12 04:38 PM
FORMELA JEAN FRANCOISDirectorJul 16Sale31.176,686208,3970Jul 18 08:40 AM